Data in Brief for research paper: Hu et al., ‘Effects and Mechanism of Ganoderma Lucidum Polysaccharides in the Treatment of Diabetic Nephropathy in Streptozotocin-Induced Diabetic Rats’
Description
Ganoderma lucidum polysaccharides (GLP) has renal protection effect but none study on the diabetic nephropathy. This study was to investigate its effect and mechanism using a diabetic rat model induced by streptozotocin (50 mg/kg, i.p.). The diabetic rats were treated with GLP (300 mg/kg/day) for 10 weeks. The blood glucose, glycated-haemoglobin, body weight, and the levels of blood creatinine, urea nitrogen, and urine protein were assessed. Also, renal pathologies were assessed by the tissue sections stained with haematoxylin-eosin, Masson's trichome and periodic acid-Schiff. The expression of p-PI3K, p-Akt, and p-mTOR, the autophagy proteins beclin-1, LC3-II, LC3-I and P62; the apoptosis-related proteins caspase-3 and caspase-9; and the inflammation markers IL-6, IL-1β, and TNF-ɑ were assessed. Results showed that GLP alleviated the impairment of renal function by reducing urinary protein excretion and the blood creatinine level and ameliorated diabetic nephropathy. The expression of p-PI3K, p-Akt, and p-mTOR in the diabetic kidney were significantly reduced in GLP treatment group compared to the without treatment group. GLP treatment activated the autophagy indicators of beclin-1 and the ratio of LC3-II/LC3-I but reduced p62; also inhibited the expression of caspase-3, caspase-9 and IL-6, IL-1β and TNF-ɑ. In conclusion, the effect of GLP amelioration diabetic nephropathy may be via inhibition of the PI3k/Akt/mTOR signaling pathway by inhibition the apoptosis and inflammation and activation the autophagy process.